Moderna (MRNA) option implied volatility elevated into investor meeting
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Evercore ISI Reiterates In Line Rating on Moderna (MRNA)
September 12, 2024 9:04 AM EDTEvercore ISI analyst Cory Kasimov reiterated an In Line rating and $105.00 price target on Moderna (NASDAQ: MRNA).
The analyst comments "Moderna published a thorough R&D overview and also updated / extended its financial guidance ahead of todays R&D Day in NYC. On the pipeline front, the most market material update is probably the lower likelihood of an early filing for INT. On the financial... More
Morgan Stanley on Moderna (MRNA): 'we expect MRNA shares to trade off this morning'
September 12, 2024 8:26 AM EDTMorgan Stanley analyst Matthew Harrison reiterated an Equalweight rating and $94.00 price target on Moderna (NASDAQ: MRNA)
The analyst comments "This morning MRNA provided updates on portfolio prioritization and new guidance ahead of the company's R&D day. MRNA plans to break even in... More
Jefferies Reiterates Buy Rating on Moderna (MRNA)
September 12, 2024 8:07 AM EDTJefferies analyst Michael Yee reiterated a Buy rating and $120.00 price target on Moderna (NASDAQ: MRNA).
The analyst comments "
Ahead of MRNA's R&D update this morning, they announced several updates with key being they plan to cut R&D spend though the bulk of the cut of $1.1B won't be until 2027. This now delays profitability until 2028 (vs prior guidance of 2026). 2025 revenue guidance is now $2.5-3.5B and below consensus of $3.8-4B too.... More
